AMENDMENT UNDER 37 C.F.R. § 1.114(c) Attorney Docket No.: Q88061

U.S. Application No.: 10/538,514

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

- 1. (currently amended): A capsule which comprises:
- a granule containing a) as an active ingredient, an indoline compound represented by the formula:

- b) D-mannitol and c) partially pregelatinized starch; and
- (2) d) a lubricant selected from magnesium stearate, calcium stearate or talc, and e) sodium lauryl sulfate, wherein 85% dissolution time is not more than 60-15 minutes in a dissolution test according to method 2 (paddle method) of Japanese pharmacopoeia in a condition using water as a test medium and a paddle speed of 50rpm.
 - 2-7. (canceled).
 - 8. (previously presented): The capsule according to claim 1, wherein the lubricant is

Attorney Docket No.: Q88061

AMENDMENT UNDER 37 C.F.R. § 1.114(c) U.S. Application No.: 10/538,514

magnesium stearate.

9. (previously presented): The capsule according to claim 8, which comprises 0.1 to 2 parts of sodium lauryl sulfate based on 1 part of magnesium stearate.

- 10. (canceled).
- (previously presented): The capsule according to claim 1, wherein the capsule is a light-shielding capsule.
- (previously presented): The capsule according to claim 11, wherein the lightshielding capsule comprises a capsule shell containing titanium oxide.
 - 13-26. (canceled).
- 27. (previously presented): The capsule according to claim 8, which comprises 0.5 to 1 part of sodium lauryl sulfate based on 1 part of magnesium stearate.
- 28. (new): The capsule according to claim 1, wherein the daily dosage of the indoline compound is in the range of 4 to 20mg.